drugset / Trial / NCT06252298
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies
Timeline
- Start
- 2024-02-28
- Primary completion
- 2025-08-28
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCTC21C | Unknown | 0.01 mg | Subcutaneous |
| Subject | SCTC21C | Unknown | 960 mg | Subcutaneous |